The molecular reach of antibodies crucially underpins their viral neutralisation capacity.

Publication date: Jan 02, 2025

Key functions of antibodies, such as viral neutralisation, depend on high-affinity binding. However, viral neutralisation poorly correlates with antigen affinity for reasons that have been unclear. Here, we use a new mechanistic model of bivalent binding to study >45 patient-isolated IgG1 antibodies interacting with SARS-CoV-2 RBD surfaces. The model provides the standard monovalent affinity/kinetics and new bivalent parameters, including the molecular reach: the maximum antigen separation enabling bivalent binding. We find large variations in these parameters across antibodies, including reach variations (22-46 nm) that exceed the physical antibody size (~15 nm). By using antigens of different physical sizes, we show that these large molecular reaches are the result of both the antibody and antigen sizes. Although viral neutralisation correlates poorly with affinity, a striking correlation is observed with molecular reach. Indeed, the molecular reach explains differences in neutralisation for antibodies binding with the same affinity to the same RBD-epitope. Thus, antibodies within an isotype class binding the same antigen can display differences in molecular reach, substantially modulating their binding and functional properties.

Open Access PDF

Concepts Keywords
Antibodies Antibodies, Neutralizing
High Antibodies, Neutralizing
Underpins Antibodies, Viral
Viral Antibodies, Viral
Antibody Affinity
Antigens, Viral
Antigens, Viral
COVID-19
Epitopes
Epitopes
Humans
Immunoglobulin G
Immunoglobulin G
Kinetics
Protein Binding
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2

Semantics

Type Source Name
drug DRUGBANK Diflunisal
disease MESH Emerging Infectious Disease
disease MESH dissociation
drug DRUGBANK Iodine
drug DRUGBANK Digoxin
drug DRUGBANK Polyethylene glycol
drug DRUGBANK Ranitidine
drug DRUGBANK Aspartame
drug DRUGBANK Trestolone
disease MESH infection
drug DRUGBANK Coenzyme M
disease IDO assay
drug DRUGBANK Esomeprazole
disease IDO pathogen
disease MESH COVID 19
disease IDO production

Original Article

(Visited 4 times, 1 visits today)